Treatment of a patient with myasthenia gravis using antibodies against CD25
Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2007.00919.x.
© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard. Objectives –
To measure clinical and immunological parameters in a patient with myasthenia gravis (MG) treated with antibodies against CD25 (basiliximab, Simulect®). Patient and methods –
Injections of basiliximab were given repeatedly together with cyclosporin A and corticosteroids for 9 months to a patient with severe MG. Her muscle function score was monitored and the immunological parameters were followed using ELISA, flow cytometry and radioimmunoassay. Results –
The patient improved moderately and corticosteroid treatment could be withdrawn. The percentage of activated CD4+ T cells decreased during treatment, while that of ‘naïve’ T cells increased. The serum levels of sCD28, sCD152, sCD80, sCD86 and IL-10 decreased. The treatment was stopped due to repeated infections. Conclusion –
Treatment with basiliximab appears to be suitable only for severely ill patients who do not respond to conventional treatments. However, careful monitoring of side effects is necessary.
Document Type: Research Article
Affiliations: 1: Immunological Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 2: Department of Neurology, Karolinska Institutet, Stockholm, Sweden
Publication date: March 1, 2008